Systemic lupus erythematosus in children: Current and emerging therapies

Lupus

Volumn 16, Issue 8, 2007, Pages 677-683

  MacDermott, E J ^a   Adams, A ^a,b   Lehman, Thomas J A ^a,b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Emerging therapy; Lupus; Pediatric; Treatment

Indexed keywords

ABATACEPT; ABETIMUS; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; AZATHIOPRINE; CD40 LIGAND MONOCLONAL ANTIBODY; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE ANTIBODY; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECULIZUMAB; EPRATUZUMAB; FLUDARABINE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 10 ANTIBODY; LJP 934; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSIDE ANALOG; PARACETAMOL; PREDNISOLONE; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE CONTROL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; IMMUNOTHERAPY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CHILD; CYCLOPHOSPHAMIDE; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; T-LYMPHOCYTES;

EID: 34548414615     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307079567     Document Type: Review

References (43)

1. Harvey AM, Shulman LE, Tumulty PH et al. Systemic lupus erythematosus. A review of the literature and clinical analysis of 138 cases. Medicine (Baltimore) 1954; 33: 291-437.
2. Cassidy JT, Petty RE. Textbook of pediatric rheumatology, 5th edition. W.B. Saunders Company, 2005.
3. Jimenez S, Cervera R, Font J, Ingelmo M. The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol 2003; 25: 3-12.
4. Rood MJ, ten Cate R, van Suijlekom-Smit LW et al. Childhood-onset systemiclupus erythematosus: clinical presentation and prognosis in 31 patients. Scand J. Rheumatol 1999; 28: 222-226.
5. Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002; 46: 436-444.
6. Lehman TJA, Onel KB. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000; 136: 243-247.
7. Adams A, MacDermott EJ, Lehman TJA. Systemic lupus erythematosus: etiology, pathogenesis, clinical manifestations, and management. In Cimaz R, Lehman TJA eds. Systemic autoimmune disease pediatrics Elsevier, 2007 (in press).
8. Isenberg D, Rahman A. Systemic lupus erythematosus. Nature Clin Pract Rheumatol 2006; 2: 145-152.
9. Adams A, MacDermott EJ, Lehman TJA. Pharmacotherapy of lupus nephritis in children: a recommended treatment approach. Drugs 2006; 66: 1191-1207.
10. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders. Arthritis Rheum 2003; 48: 1484-1492.
11. Looney RJ, Anolik JH, Campbell D et al. B-cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose escalation trial of Rituximab. Arthritis Rheum 2004; 50: 2580-2525.
12. Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B-cell depletion therapy is preceded by down regulation of the t-cell costimulatory molecule CD40 ligand: an open label trial. Arthritis Rheum 2005; 52: 501-513.
13. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005; 17: 550-557.
14. Anolik JH, Barnard J, Cappione A et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthrtis Rheum 2004; 50: 3580-3590.
15. Marks SD, Patey S, Brogan PA et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005; 52: 3168-3174.
16. Barillas-Arias L, Adams A, Angeles S, MacDermott EJ, Barinstein L, Lehman TJA. Combination of rituximab and cyclophosphamide for the treatment of childhood onset systemic lupus erythematosus. Arthritis Rheum 2006; 54(Suppl): S689-690 (abstract).
17. Alarcon-Segovia D, Tumlin JA, Furie RA et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomised double-blind placebo-controlled study. Arthritis Rheum 2003; 48: 442-454.
18. Weisman MH, Bluestein HG, Berner CM, de Haan Ha. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997; 24: 314-318.
19. Linnik MD, Hu JZ, Heilbrunn KR et al. Relationship between antidouble stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52: 1129-1137.
20. Tahir H, Isenberg DA. Novel therapies in lupus nephritis. Lupus 2005; 14: 77-82.
21. Kimball JA, Pescovitz MD, Book BK, Normal DJ. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation 1995; 60: 1379-1383.
22. Ginzler EMAC, Buyon J, Dooley MA et al. A multicenter study of mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis (LN); preliminary results. Arthritis Rheum 2003; 48 (Suppl): S647 (abstract).
23. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980.
24. Buratti S, Szer S, Spencer CH, Bartosh S, Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001; 28: 2103-2108.
25. Tsokos GC, Mitchell JP, Juang YT. T cell abnormalities in human and mouse lupus: intrinsic and extrinsic. Curr Opin Rheumatol 2003; 15: 542-547.
26. Jury EC, Kabouridis PS, Flores-Borja F et al. Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 2004; 113: 1176-1187.
27. Ciftci E, Yalcinkaya F, Ince E et al. Pulmonary involvement in childhood-onset systemic lupus erythematosus: a report of five cases. Rheumatology (Oxford), 2004; 43: 587-591.
28. Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D. IDEC-131 Lupus study group. Treatment of systemic lupus erythematosus by inhibition of T cell co-stimulation with antiCD154: a randomised double-blind, placebo controlled trial. Arthritis Rheum 2002; 46: 3251-3258.
29. Boumpas DT, Furie R, Manzi S et al. A short course of BG9588 (anti-CD40-ligand antibody)improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48: 719-727.
30. Finck B, Linsley P, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994; 265: 1225-1227.
31. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005; 44: 1542-1545.
32. Hooks JJ, Moustsopoulos HM, Geis SA, Stahl NI, Decker JI, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301: 5-8.
33. Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990; 227: 207-210.
34. Santiago-Raber ML, Baccala R, Harldsson KM et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197: 777-788.
35. Baechler EC, Batliwalla FM, Karypis G et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. PNAS 2003; 100: 2610-2615.
36. Kirou KA, Lee C, George S et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3958-3967.
37. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52: 1491-1503.
38. Smolen JS, Steiner G, Aringer M. Anti-cytokine therapy in systemic-lupus erythematosus. Lupus 2005; 14: 189-191.
39. Stohl W. A therapeutic role for Blys. Lupus 2004; 13: 317-322.
40. Stohl W. Systemic lupus erythematosus: a blissless disease of too much BLys (B lymphocyte stimulator) protein. Curr Opin Rheumatol 2002; 14: 522-528.
41. Merrill J. BLyS antagonists and peptide tolerance induction. Lupus 2005; 14: 204-209.
42. Kalsi JK, Grossman J, Kim J et al. Peptides from antibodies to DNA elicit cytokine release from peripheral blood mononuclear cells of patients with systemic lupus erythematosus: relation of cytokine pattern to disease duration. Lupus 2004; 13: 490-500.
43. Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 166-173.